New drugs that might fly in 2022

Posted 21 December 2021 AM

Nearly half of the new medicines recommended for approval by the CHMP this month, have either already been green-lighted by the TGA or are currently under review, signalling Australia is catching up to its European counterpart and hinting at what is likely to come early 2022.

In its last meeting for the year, the EMA's advisory committee gave the nod to nine new medicines, three of which have been TGA approved, including Pfizer's once-weekly, long-acting, recombinant growth hormone Ngenla, and Bayer's treatment for chronic kidney disease associated with type 2 diabetes in adults, Kerendia. Both medicines were TGA approved in November.

To see the whole article, please login

MORE NEWS

Email this article to a friend

From:

Subject

Friend's email

Message to go with the article

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.

Skip password for now